 NantKwest, Inc. NASDAQ: NK and ImmunityBio, Inc., clinical-stage immunotherapy companies within the NantWorks family of companies, today announced they are in active discussions with the U.S. Food and Drug Administration FDA for vaccines and therapeutics to combat COVID-19. 